Keros Therapeutics amends bylaws to update director nomination procedures, universal proxy rules

Keros Therapeutics, Inc.

Updated advance notice provisions for director nominations, including requirements under Rule 14a-19 and limiting nominees to board seats available.
Enhanced disclosure requirements for nominating stockholders and nominees, with obligation to update and supplement information.
Clarified procedures for stockholder meetings, including meeting place, adjournment, notices, conduct, and stockholder lists.
Conforming edits and other clarifying updates to improve consistency across bylaws.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Keros Therapeutics, Inc.: Amended and Restated Bylaws to update advance notice provisions for director nominations, enhance disclosure requirements, clarify stockholder meeting procedures, and make conforming edits (effective 2025-03-05).

Change: bylaw amendment
Effective: 2025-03-05

Exact text from the filing

On March 5, 2025, in connection with a periodic review of corporate governance matters, the board of directors (the “Board”) of Keros Therapeutics, Inc. (the “Company”) approved and adopted the Amended and Restated Bylaws of the Company (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

Browse all governance changes →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-25-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.